Parsons Supporting U.S. Defense Health Agency On $10 Billion Omnibus IV Contract

CENTREVILLE, Va., June 16, 2022 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) was selected by the U.S. Defense Health Agency (DHA) to provide health-related research and development and additional activities of interest for the Department of Defense and the Military Healthcare System. The $10 billion ceiling value Omnibus IV is a five-year multiple-award indefinite delivery/indefinite quantity contract with one five-year option period.

“The Parsons team stands ready to deliver on DHA’s mission of providing our country’s military health providers cutting-edge tools to deliver optimal care to service members,” said Jon Moretta, president, engineered systems for Parsons. “Our biosurveillance and environmental services group offers a broad spectrum of innovative technical and support capabilities that will help maximize DHA’s investment in force readiness, health, and resilience.”

The Omnibus IV Military Medical Research and Development contract is a continuation of successful past government investments focused on the discovery and integration of medical innovations and material solutions to continually enhance force health readiness, resilience, and rehabilitation. The contract’s program areas support migration of new or existing research and technology into military medical practice, and include medical simulation technology, research into infectious diseases and radiation effects, battlefield healthcare, clinical medicine, chemical and biological readiness, genomics and omics-based research, and science technologies. Elements of these program areas fall into four well-defined but not mutually exclusive market segments. Parsons will compete for task orders in Market Segment 2, R&D Support Services.

For decades, Parsons has delivered a better world through innovations that protect human health like research and development for infectious disease surveillance, bioinformatics, biological detection, immune and molecular diagnostics development and testing, PFAS mitigation, aerospace medical and environmental health effects, and undersea and high-altitude injury and performance research for military readiness.

To learn more about Parsons’ biosurveillance and environmental capabilities, visit www.parsons.com/biosurveillance/.

About Parsons:

Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, connected infrastructure, and smart cities. Please visit parsons.com, and follow us on LinkedIn and Facebook to learn how we’re making an impact.